Antibodies create broad SARS immune response: study

By The Science Advisory Board staff writers

August 11, 2022 -- Scientists from Scripps Research have discovered certain antibodies are capable of immunity against many different SARS-CoV-2 variants, as well as other SARS viruses like SARS-CoV-1.

Certain animals are more capable of producing these broad antibodies and during their investigation, the study team identified the antibody structures that provide this more comprehensive immune response, which has implications for vaccine production (Science Translational Medicine, August 10, 2022).

Specifically, these neutralizing antibodies recognize a viral spike region that is relatively more conserved or present across SARS viruses and less likely to mutate. In the study, rhesus macaque monkeys were immunized with the SARS-CoV-2 spike protein and two vaccine shots were administered that resemble the current mRNA vaccines available for humans. However, unlike humans, the macaques had a broad neutralizing antibody response against the virus due to their antibodies recognizing the conserved region, in this case the angiotensin converting enzyme 2 receptor binding site.

The majority of human antibodies do not target this region and that suggests additional strategies to coax the human immune system into recognizing this particular region of the virus will be helpful for vaccine production, according to the scientists.

However, the genetics between humans and monkeys differ so more investigation is needed, not only for identifying new strategies against SARS viruses, but also for making sure the best translational models are used.

Studies uncover findings on antibody responses, immunity
Findings from two studies add to a growing body of knowledge that is essential for guiding public health initiatives and might one day enable clinicians...
Current COVID-19 boosters provide protections against serious infection: study
Despite the evolution of the SARS-CoV-2 pandemic coronavirus, a new laboratory study conducted by a team of international researchers suggests current...
NIH study shows how immune response to COVID-19 damages the brain
A National Institutes of Health (NIH) study, which examined brain changes in nine people who died suddenly after contracting COVID-19, found that antibodies...
mRNA-based therapeutics pioneer innovation in the biopharmaceutical industry
In the age of COVID-19, many novel therapeutics have been brought to the forefront, most notably mRNA-based therapies. This technology has been used in...
Technology upgrades needed to address future pandemics, GAO report says
Vaccine R&D and manufacturing face many challenges despite the success of COVID-19 vaccines. This is according to a new U.S. Government Accountability...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter